Akebia’s Anemia Treatment in CKD Patients Facing Further Delay

The targeted radiotherapy candidate proved a resounding success, with an impressive 75% of patients achieving initial remission after bone marrow transplant (BMT), compared to a mere 6.3% in the control group. These results demonstrate the efficacy of the radiotherapy candidate in treating the condition.

After six months of treatment, Actinium Pharmaceuticals’ Iomab-B has achieved a major milestone in the Phase III SIERRA trial, proving to be a successful solution for patients suffering from elapsed or refractory acute myeloid leukemia (r/r AML). The trial found that Iomab-B was able to deliver durable Complete Remissions (dCR) to these patients, offering hope and a much-needed breakthrough in AML care.

The encouraging results of Actinium’s Iomab-B cohort study have given hope to many. Of the patients enrolled in the study, 22% achieved a complete remission that lasted through six months. These patients showed a remarkable survival rate of 90% at one year and 60% at two years, and the median overall survival has yet to be determined. It is a promising sign for those seeking a long-term solution to their health issues.

The SIERRA trial, a pivotal, randomized and controlled experiment, aimed to assess the effectiveness of Iomab-B in treating 153 elderly patients with relapsed/refractory Acute Myeloid Leukemia. Participants aged 55 and older were compared against a group receiving their physician’s chosen salvage therapy. The results of the study could potentially revolutionize the treatment of this deadly disease.

SIERRA assessed the efficacy of the therapy using two secondary endpoints, event-free and overall survival. Results showed that compared to the control arm, treatment with Iomab-B dramatically reduced the probability of any event occurring by a staggering 78%. These events included death, relapse or not receiving BMT within the six-month period.

Iomab-B demonstrated remarkable results in a clinical trial, doubling the one-year and median overall survival compared to the control group. Moreover, all recipients of the radiotherapy were successfully able to undergo bone marrow transplantation, compared to only 18% of the control group. These findings indicate that Iomab-B may be a promising option for patients with relapsed or refractory acute myeloid leukemia.

Actinium’s research indicates that Iomab-B is associated with significantly lower rates of treatment-related adverse events, including febrile neutropenia, mucositis and acute graft-versus-host disease. This is great news for those who are undergoing treatment for their medical condition.

Sergio Giralt, M.D., Deputy Head of the Division of Hematologic Malignancies and Attending Physician of the Adult BMT Service at Memorial Sloan Kettering Cancer Center, heralds the dCR and two-year survival data as “practice changing” – a remarkable breakthrough in the medical field.

Iomab-B has demonstrated a safety profile that is second to none, and most importantly, a significantly improved overall and event-free survival rate. With such promising results, Iomab-B is an ideal candidate to become the new standard of care for active, relapsed/refractory acute myeloid leukemia (AML).

Iomab-B is a groundbreaking therapy that has the potential to offer curative bone marrow transplants to those who cannot access them. By rapidly and substantially depleting a patient’s immune, blood cancer and bone marrow cells, Iomab-B has been shown to offer near-universal access to BMT, leading to improved survival outcomes. This revolutionary treatment is set to revolutionize the field of transplant medicine.

Actinium is on the cusp of a major milestone: submitting a Biologics License Application for Iomab-B in 2023. This will be a defining moment in the company’s history, offering hope to patients in need of life-saving treatments.

Leave a Comment